



Correction to: The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders

Adam J. Schwarz¹

Published online: 26 April 2021

© The American Society for Experimental NeuroTherapeutics, Inc. 2021

Correction to: Neurotherapeutics (2021)
<https://doi.org/10.1007/s13311-021-01027-4>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The published version of this article contains an incorrect statement about the amyloid load methodology: "...100 on the A β L scale reflects the maximum load. This scale may thus be prone to a ceiling effect in individuals with near-maximal amyloid load...". In fact, the amyloid load metric is a continuous variable with values that can exceed 100 and thus is not prone to a ceiling effect.

The original version has been corrected.

The original article can be found online at <https://doi.org/10.1007/s13311-021-01027-4>.

✉ Adam J. Schwarz
adam.schwarz@takeda.com

¹ Takeda Pharmaceuticals Ltd, 40 Landsdowne Street,
Cambridge, MA 02139, USA